Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples

Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples

Abstract INTRODUCTION We evaluated the diagnostic performance of two commercial plasma p‐tau217 immunoassays compared to cerebrospinal fluid (CSF) testing and neuropathology. METHODS One hundred and seventy plasma samples from the University of British Columbia Hospital Clinic for Alzheimer's (...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna E. Mammel, Ging‐Yuek Robin Hsiung, Ali Mousavi, Kelsey Hallett, Ian R. Mackenzie, Veronica Hirsch‐Reinshagen, Don Biehl, Pradip Gill, Mary Encarnacion, Hans Frykman
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Alzheimer's disease
CSF Aβ 42 to 40 ratio
CSF p‐tau181
immunoassays
neuropathology diagnosis
plasma p‐tau217
Online Access:https://doi.org/10.1002/dad2.70070
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items